Table 2.
Prognostic factors: univariate analysis
|
Characteristics |
Local control |
Overall survival |
|||
|---|---|---|---|---|---|
| 2-year (%) | *P-value | 2-year (%) | *P-value | ||
| Age (years) |
≤ 60 |
79.5 |
59.6 |
||
| > 60 |
92.8 |
0.019 |
66.3 |
NS |
|
| Gender |
Male |
83.3 |
|
57.8 |
|
| Female |
95.7 |
NS |
76.8 |
NS |
|
| Diagnosis history at SBRT |
Initially diagnosed |
96.2 |
67.9 |
||
| Recurrence |
82.3 |
NS |
60.3 |
NS |
|
| Child-Turcotte-Pugh score |
A5, 6 |
85.3 |
60.1 |
||
| B7 |
100.0 |
NS |
87.5 |
NS |
|
| Portal vein tumor thrombosis |
Yes |
88.9 |
62.9 |
|
|
| No |
86.4 |
NS |
62.5 |
NS |
|
| Alpha-fetoprotein (IU/ml) |
≤ 200 |
88.4 |
66.3 |
|
|
| > 200 |
81.5 |
NS |
53.8 |
NS |
|
| AJCC stage |
T1 |
93.7 |
71.3 |
|
|
| T2, 3 |
73.2 |
0.031 |
53.8 |
NS |
|
| BCLC stage |
A |
93.7 |
74.7 |
|
|
| B, C |
78.8 |
0.018 |
51.0 |
0.011 |
|
| Okuda stage |
I |
89.1 |
65.4 |
||
| II |
77.9 |
NS |
55.0 |
NS |
|
| CLIP score |
0 |
85.1 |
66.6 |
||
| 1, 2 |
88.6 |
NS |
59.4 |
NS |
|
| Longest diameter (cm) |
≤ 5.0 |
90.2 |
69.4 |
||
| > 5.0 |
63.3 |
0.015 |
33.3 |
0.012 |
|
| No. of previous TACE sessions |
≤ 2 |
95.7 |
|
69.6 |
|
| > 2 |
77.2 |
0.022 |
54.9 |
0.023 |
|
| SBRT dose (Gy) |
< 45 |
64.3 |
30.0 |
||
| 45–54 |
78.3 |
0.009 |
64.3 |
<0.001 |
|
| > 54 | 100.0 | 71.3 | |||
Abbreviations: SBRT stereotactic body radiotherapy, TACE transarterial chemoembolization, AJCC American Joint Committee on Cancer, BCLC Barcelona Clinic Liver Cancer, CLIP Cancer of the Liver Italian Program; NS not significant (p > 0.05).
*P-value was calculated by log-rank test.